Suppr超能文献

西沙必利与雷尼替丁治疗功能性消化不良的比较。

Cisapride compared with ranitidine in the treatment of functional dyspepsia.

作者信息

Carvalhinhos A, Fidalgo P, Freire A, Matos L

机构信息

Department of Medicine II, Santa Maria Hospital, Lisbon, Portugal.

出版信息

Eur J Gastroenterol Hepatol. 1995 May;7(5):411-7.

PMID:7614103
Abstract

OBJECTIVE

To compare the efficacy of the prokinetic drug cisapride and the antisecretory agent ranitidine in relieving symptoms of functional dyspepsia, as well as their effect on the recurrence of symptoms after the discontinuation of treatment.

DESIGN

A randomized double-blind parallel-group trial of cisapride 30 mg daily and ranitidine 300 mg daily given for 2, 4 or 8 weeks, followed by a 4-week drug-free follow-up of the patients with a good or excellent response. Rescue antacid tablets were allowed only if pain was unbearable.

PATIENTS

A total of 203 patients (99 cisapride, 104 ranitidine) with symptoms of functional dyspepsia for more than 4 weeks, after the exclusion of organic disease by endoscopy and sonography or radiology.

RESULTS

Cisapride and ranitidine improved the symptoms of diffuse epigastric pain, postprandial epigastric fullness, epigastric distension, belching, heartburn, regurgitation, and nausea when compared with baseline. Pain at night and gastric discomfort also greatly improved. Cisapride produced a greater reduction in epigastric pain (P = 0.07) and epigastric distension (P = 0.03) scores than ranitidine. Both drugs were equally effective in reducing the concomitant reflux-like symptoms of heartburn and regurgitation. At week 8, 87% of cisapride patients versus 61% of ranitidine patients had an excellent or good result. The deterioration of symptoms during the follow-up phase was limited in both groups. However, after the withdrawal of medication there was a greater reduction in scores in the cisapride group than in the ranitidine group for diffuse epigastric pain (P = 0.05), epigastric distension (P = 0.002), the cluster of six symptoms of epigastric discomfort (P = 0.05), and the cluster of all nine upper gastrointestinal symptoms (P = 0.06). Adverse events occurred in 15 cisapride patients and 18 ranitidine patients, and two of the ranitidine patients were withdrawn from treatment.

CONCLUSIONS

Although cisapride and ranitidine both improved the symptoms of functional dyspepsia, cisapride was superior to ranitidine, particularly on the combined evaluation of the response to treatment and the recurrence of symptoms.

摘要

目的

比较促动力药物西沙必利和抗分泌药物雷尼替丁缓解功能性消化不良症状的疗效,以及它们对治疗停药后症状复发的影响。

设计

一项随机双盲平行组试验,每日给予西沙必利30毫克和雷尼替丁300毫克,持续2、4或8周,随后对反应良好或优秀的患者进行4周的停药随访。仅在疼痛无法忍受时允许使用急救抗酸片。

患者

共有203例功能性消化不良症状持续超过4周的患者(99例西沙必利组,104例雷尼替丁组),经内镜检查、超声检查或放射学检查排除器质性疾病。

结果

与基线相比,西沙必利和雷尼替丁均改善了弥漫性上腹部疼痛、餐后上腹部饱胀、上腹部膨胀、嗳气、烧心、反流和恶心等症状。夜间疼痛和胃部不适也有显著改善。西沙必利在上腹部疼痛(P = 0.07)和上腹部膨胀(P = 0.03)评分方面的降低幅度大于雷尼替丁。两种药物在减轻烧心和反流等伴随的类似反流症状方面同样有效。在第8周时,87%的西沙必利组患者与61%的雷尼替丁组患者效果良好或优秀。两组在随访阶段症状的恶化均有限。然而,停药后,西沙必利组在弥漫性上腹部疼痛(P = 0.05)、上腹部膨胀(P = 0.002)、六种上腹部不适症状组合(P = 0.05)以及所有九种上消化道症状组合(P = 0.06)的评分降低幅度大于雷尼替丁组。15例西沙必利组患者和18例雷尼替丁组患者出现不良事件,两名雷尼替丁组患者退出治疗。

结论

尽管西沙必利和雷尼替丁均改善了功能性消化不良症状,但西沙必利优于雷尼替丁,特别是在治疗反应和症状复发的综合评估方面。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验